BIONTECH SE ADR
BIONTECH SE ADR
Action · US09075V1026 · BNTX · A2PSR2 (XFRA)
Aperçu Indicateurs financiers
95,25 EUR
-0,56 % -0,54 EUR
Cours de clôture XFRA 06.06.2025: 96,45 EUR
Frankfurt (XNAS) · Cours et graphiques actuels sur MoneyPeak
06.06.2025 22:29

Cours actuels de BIONTECH SE ADR

BourseTickerDeviseDernier échangeCoursVariation journalière
XNAS: NASDAQ
NASDAQ
BNTX
USD
06.06.2025 22:29
108,54 USD
110,15 USD
-1,46 %
XFRA: Frankfurt
Frankfurt
22UA.F
EUR
06.06.2025 17:13
96,45 EUR
97,75 EUR
-1,33 %

Performance

Jour Semaine Mois 3 mois 6 mois 1 an 5 ans
0,00 % 12,96 % 13,69 % -6,90 % -17,32 % 1,06 % 118,66 %

Profil de l'entreprise pour BIONTECH SE ADR Action

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Fonds investis

Les fonds suivants ont investi dans : BIONTECH SE ADR investi :

Fonds
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. en millions
862,43
Part (%)
2,02 %

Données de l'entreprise

Nom BIONTECH SE ADR
Société BioNTech SE
Symbole BNTX
Site web https://www.biontech.de
Marché d'origine XFRA Frankfurt
WKN A2PSR2
ISIN US09075V1026
Type de titre Action
Secteur Healthcare
Industrie Biotechnology
PDG Dr. Ugur Sahin M.D.
Capitalisation boursière 21 Mrd.
Pays Allemagne
Devise EUR
Employés 6,8 T
Adresse An der Goldgrube 12, 55131 Mainz
Date d'introduction en bourse 2019-10-11

Symboles boursiers

Nom Symbole
Frankfurt 22UA.F
NASDAQ BNTX
XETRA 22UA.DE

Autres actions

Les investisseurs qui détiennent BIONTECH SE ADR ont également les actions suivantes dans leur portefeuille :
ALIBABA GR. SP.ADR 8
ALIBABA GR. SP.ADR 8 Action
ALPHABET INC - CLASS A
ALPHABET INC - CLASS A Action
AMAZON.CO INC
AMAZON.CO INC Action
APPLE INC
APPLE INC Action
DE000MA3XQW9
DE000MA3XQW9 Unbekannt
ENDRA Life Sciences Inc. - Common Stock
ENDRA Life Sciences Inc. - Common Stock Action
KIATNAKIN PH-FOREIGN-BA10
KIATNAKIN PH-FOREIGN-BA10 Action
META PLATFORMS INC
META PLATFORMS INC Action
MICROSOFT CORP
MICROSOFT CORP Action
MOELIS CO - CLASS A
MOELIS CO - CLASS A Action
NVIDIA CORP
NVIDIA CORP Action
PAYPAL INC
PAYPAL INC Action
SQUARE INC A
SQUARE INC A Action
TESLA INC
TESLA INC Action
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles. Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Mentions légales Protection des données Blog Communauté Retour d'information Changelog
Im App Store herunterladen Bei Google Play herunterladen
Tous droits réservés © LCP GmbH 2025